Annexin Pharmaceuticals AB (ANNX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.716x

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has a cash flow conversion efficiency ratio of -0.716x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.33 Million ≈ $-1.11 Million USD) by net assets (Skr14.42 Million ≈ $1.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ANNX net asset quality index to measure how much of total assets are equity-financed.

Annexin Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Annexin Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Annexin Pharmaceuticals AB (ANNX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annexin Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Perpetual Resources Ltd AU:PEC	-0.164x
Australian Dairy Nutritionals Ltd AU:AHF	-0.080x
Lisata Therapeutics Inc. NASDAQ:LSTA	-0.195x
Reabold Resources Plc LSE:RBD	-0.032x
Taitron Components Incorporated NASDAQ:TAIT	0.026x
Aston Bay Holdings Ltd V:BAY	-0.716x
Q Interline AS CO:QINTER	-3.097x
Kordellos Ch. Bros S.A AT:KORDE	0.075x

Annual Cash Flow Conversion Efficiency for Annexin Pharmaceuticals AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of Annexin Pharmaceuticals AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Annexin Pharmaceuticals AB market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr24.93 Million ≈ $2.68 Million	Skr-36.92 Million ≈ $-3.97 Million	-1.481x	+59.57%
2024-12-31	Skr13.71 Million ≈ $1.48 Million	Skr-50.23 Million ≈ $-5.41 Million	-3.663x	-58.77%
2023-12-31	Skr18.81 Million ≈ $2.02 Million	Skr-43.40 Million ≈ $-4.67 Million	-2.307x	-68.98%
2022-12-31	Skr30.15 Million ≈ $3.24 Million	Skr-41.16 Million ≈ $-4.43 Million	-1.365x	-41.68%
2021-12-31	Skr46.73 Million ≈ $5.03 Million	Skr-45.02 Million ≈ $-4.85 Million	-0.964x	+49.27%
2020-12-31	Skr20.64 Million ≈ $2.22 Million	Skr-39.20 Million ≈ $-4.22 Million	-1.899x	+15.17%
2019-12-31	Skr11.49 Million ≈ $1.24 Million	Skr-25.73 Million ≈ $-2.77 Million	-2.239x	-213.04%
2018-12-31	Skr39.85 Million ≈ $4.29 Million	Skr-28.50 Million ≈ $-3.07 Million	-0.715x	+55.27%
2017-12-31	Skr24.44 Million ≈ $2.63 Million	Skr-39.08 Million ≈ $-4.21 Million	-1.599x	-150.32%
2016-12-31	Skr15.57 Million ≈ $1.68 Million	Skr-9.95 Million ≈ $-1.07 Million	-0.639x	-101.75%
2015-12-31	Skr-137.00K ≈ $-14.74K	Skr-5.01 Million ≈ $-539.37K	36.584x	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$9.15 Million

Skr85.06 Million SEK

Market Cap Rank

#27249 Global

#593 in Sweden

Share Price

Skr12.05

Change (1 day)

-1.63%

52-Week Range

Skr12.00 - Skr31.80

All Time High

Skr37.00